Treatment of patients with chronic hepatitis C who failed the triple therapy with first generation of protease inhibitors is not still defined. The combined use of sofosbuvir (SOF) and daclatasvir (DCV) seems to be promising due to higher genetic barrier, good tolerance and effectiveness.

Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors

BOGLIONE, Lucio
First
;
CARDELLINO, Chiara Simona;DE NICOLO', AMEDEO;CUSATO, JESSICA;CARCIERI, CHIARA;DI PERRI, Giovanni;D'AVOLIO, ANTONIO
Last
2017-01-01

Abstract

Treatment of patients with chronic hepatitis C who failed the triple therapy with first generation of protease inhibitors is not still defined. The combined use of sofosbuvir (SOF) and daclatasvir (DCV) seems to be promising due to higher genetic barrier, good tolerance and effectiveness.
2017
45
1
103
106
Cirrhotic; Daclatasvir; HCV; Protease inhibitors; Ribavirin
Boglione, Lucio; Pinna, Simone Mornese; Cardellino, Chiara Simona; De Nicolò, Amedeo; Cusato, Jessica; Carcieri, Chiara; Cariti, Giuseppe; Di Perri, Giovanni; D'Avolio, Antonio
File in questo prodotto:
File Dimensione Formato  
10.1007%2Fs15010-016-0962-3.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 412.05 kB
Formato Adobe PDF
412.05 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1618803
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact